DOCSLIB.ORG

IRISH PHARMACY JOURNAL Official Journal of the Pharmaceutical Society of Ireland

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IRISH PHARMACY JOURNAL Official Journal of the Pharmaceutical Society of Ireland IRISH PHARMACY JOURNAL Official Journal of the Pharmaceutical Society of Ireland Index - Volume 85 January to December, 2007 Compiled by Carol Keogh The Pharmaceutical Society of Ireland, 18 Shrewsbury Road, Ballsbridge, Dublin 4, Republic of Ireland IRISH PHARMACY JOURNAL INDEX TO VOLUME 85 Page numbers Issue 1 – 40 January ‘07 R eaders should note that signed articles are indexed under two entries – the name of the contributor and the 41- 84 February ‘07 subject of the article. All references to “Society” refer to the Pharmaceutical Society of Ireland. All references to 85 - 128 March ‘07 “Council” refer to the Council of the Pharmaceutical Society of Ireland. Cross-references are listed in soft brackets 129 - 180 April ‘07 following each entry. Hard brackets indicate parentheses in a title. 181 - 220 May ‘07 ABBREVIATIONS: The following abbreviations are used in the index: 221 - 264 June ‘07 265 - 328 July ‘07 ADR Adverse Drug Reactions MHRA Medicines and Healthcare Regulatory Agency (UK) ADVANCE Action in Diabetes and Vascular Disease: perindopril/ MMR Measles, Mumps and Rubella 329 - 376 Aug/Sept ‘07 indapamide and Diamicron MR Controlled Evacuation MRII Medical Representatives’ Institute of Ireland 377 - 416 October ‘07 AED Automated External Defibrillator MRSA methicillin -resistant Staphylococcus aureus 417 - 460 November ‘07 AGM Annual General Meeting NAPHT National Association of Hospital Pharmacy Technicians NCPE National Centre for Pharmacoeconomics CHMP Committee for Human Medicinal Products 461 - 500 Dec ‘07/Jan ‘08 NHS National Health Service COPD Chronic Obstructive Pulmonary Disease DIT Dublin Institute of Technology OAB Overactive bladder EC European Commission OHLSC Our Lady’s Hospital for Sick Children EMCDDA European Monitoring Centre for Drugs & Drug Addiction OTC Office of Tobacco Control EMEA European Medicines Agency OTC Over the Counter EU European Union PCDS Primary Care Dermatology Society FDA Food & Drug Administration (US) PREVAIL Prevention of VTE after Acute Ischaemic Stroke with FIP Federation Internationale des Pharmaceutiques LMWH Enoxaparin RA Rheumatoid Arthritis FSAI Food Safety Authority of Ireland HIQA Health Information and Quality Authority PSI Pharmaceutical Society of Ireland HPAI Hospital Pharmacists’ Association of Ireland R&D Research and Development HSE Health Service Executive RCSI Royal College of Surgeons in Ireland HSP Health Support Programme RFID Radio Frequency Identification IHF Irish Heart Foundation RPSGB Royal Pharmaceutical Society of Great Britain IMB Irish Medicines Board SOPs Standard Operating Procedures IPA Irish Patients’ Association TB Tuberculosis IPHA Irish Pharmaceutical Healthcare Association TCD Trinity College Dublin TCM Traditional Chinese Medicine PMII Pharmaceutical Managers’ Institute of Ireland POM Prescription-only medicine UCC University College Cork MCQs Multiple Choice Questions UK United Kingdom A Arthritis Betaferon® Orencia® (abatacept) - treatment for RA Biopharmaceuticals – the new weapon of choice Adalimumab (Orencia) 371 in the battle against disease CHMP give Humira® (adalimumab) positive Aseptic Compounding (Collins, R.) 166-169 opinion for the treatment of Crohn’s Disease Designing a capacity plan for the Aseptic The Science behind Biopharmaceuticals (CHMP/Crohn’s Disease) 238 Compounding Unit in St. James’s Hospital (Cryan, S.A./Moran, P.J.) 202-204 Addiction (Capacity Planning/Hospital Pharmacy Issue/ Blood Pressure Suboxone® (buprenorphine/naloxone) – a new O’Boyle, N./St. James’s Hospital) 303-306 Impact of a community pharmacy-directed weight alternative to methadone (Buprenorphine/ Astellas European Foundation support TCD management programme on blood pressure Methadone) 124 School of Pharmacy research (R&D/ findings (Obesity/O’Brien, C./ Young Scientist Project [2007] – Codeine Schools) 102 Weight Management) 240-246 Addiction in Ireland (Codeine) 102 Asthma Trial shows benefits of blood pressure lowering ADR (see also Adverse Drug Reactions) Facts about asthma in Ireland 286 treatment for over-80s (Clinical Trial) 494 IMB launches new website with online ADR Singulair now available for children aged 2-14 Blood Tests reporting (IMB) 432 years with mild persistent Asthma Reflotron Plus – on the spot blood test results ADVANCE study shows benefits of perindopril/ (Paediatrics/Singulair) 36, 81 (Point of Care/Reflotron Plus) 321 indapamide (Perindopril) 454 Audit Committee Bonviva® studies show significant benefit in Adverse Drug Reactions and the role of the Fostering the principles of good governance reducing risk of non-vertebral fractures Pharmacist – Hepatotoxicity (Henman, M./ (Interview/MacHale, S.) 477-478 (Osteoporosis) 192 Hepatotoxicity/Pharmacovigilance) 436-442 Avastin Book Reviews Advertising (of medicines) Avastin – further indication approved 192 Antimicrobial Pharmacodynamics in Theory and For better or for worse – medicine advertising and Avastin – further positive results as a co-treatment Clinical Practice (2nd Edition) Nightingale, C., medicine use (Zephyr) 82 for lung and renal cancers (Cancer) 234 Ambrose, P. et al 449 AED’s Awards Applications of LC-MS in Toxicology Prevention of Sudden Cardiac Death – the role of Cork-based pharmacist wins top accolade 12-13 Polettini, A. {Ed.} 118 the Community Pharmacy (Cardiac/ Inaugural IPOS Pharmacy Excellence Awards Concise Clinical Pharmacology Greenstein, B. & Eggers, S.) 247 -250 (IPOS) 17 Greenstein, A. 172 Alcohol and Pregnancy (Pregnancy) 386 International Award for Mater Hospital Dietary Supplements (3rd Edition) Mason, P. 366 Allergy Pharmacist (Mater Misericordiae Hospital) 338 Drug-Induced Diseases – Prevention, Detection Cow’s Milk Allergy in Infants (Paediatrics) 325 La Roche-Posay International award for Alan and Management Tisdale, J.E., Mille, D.A. 118 GRAZAX® - positive second year results Irvine (OLHSC) 21 Endotoxins: Pyrogens, LAL Testing and (GRAZAX®) 110 Pharmaceutical Manufacturing Technology Depyrogenation Williams, K.L. {Ed.} 368 Analgesics Awards Ceremony [TCD] (Schools) 170 Handbook of Poisonous & Injurious Plants (2nd Guidance on OTC Analgesia in Pain Practice of Pharmacy Committee: Announcement Edition) Nelson, L.S., Shih, R.D., Management Launched (OTC/Pain) 152 of Funding Awards for Practice Based Balick, M.J. 212 Versatis® - Lidocaine -medicated plaster approved Research (Practice of Pharmacy) 90-92 Irish Medicines Formulary (2nd Edition) by MHRA (Lidocaine/Versatis) 80 Cock-Wall, A. 408 Anastrozole Managing Anticoagulant Patients in the Hospital Long-term safety data for Arimidex™ Battaglia, D. {Ed.} 406 [anastrozole] reinforce patient benefits B The Maudsley Prescribing Guidelines (9th Edition) (Cancer) 66 Taylor, D., Paton, C., Kerwin, R. {Eds.} 368 Antibiotics Baggot, J. MCQs in Clinical Pharmacy Azzopardi, L.M. GPs admit over-prescribing antibiotics (Over- International Suicide Prevention Conference 226 {Ed.} 319 nd prescribing) 428 Suicide prevention: what can we do – as people, Neutraceuticals (2 Edition) Lockwood, B. 366 Appointments as pharmacists? (Suicide) 400-402 Palliative Care: Core Skills and Clinical HIQA Director of Health Technology Assessment Bar coding (see Technology) Competencies Emanuel, L.L., Librach, S.L. (HIQA) 340 BD Diagnostics {Eds.} 449 Irish Pharmaceutical Healthcare Association BD’s MRSA test gets EU approval (MRSA) 238 Patient Compliance with Medications: Issues and (IPHA) 340 Benevolent Fund Opportunities Fincham, J.E. {Ed.} 450 New member of IPHA appointed to the Board of Benevolent Fund AGM 386 Pharmacy and the US healthcare System (3rd Directors (IPHA) 257 Benevolent Fund Golf Classic, 2007 282 Edition) Smith, M.I., Wertheimer, A.I., Pfizer appoints new Country Manager Benevolent Fund: let them know they’re not Fincham, J.E. {Eds.} 32 (Pfizer) 256 forgotten (Dowd, M./Interview) 451-452 Psoriasis – at your fingertips Mitchell, T., Arimidex™ (see Anastrozole) Penzer, R. 212 Rules & Guidance for Pharmaceutical Chronic Pain (see Pain) Cramp Distributors 2007 Pharmaceutical Press 366 Clarymist - New Dry Eye spray treatment Botox effective at relieving writer’s cramp Rules and Guidance for Pharmaceutical (Eyes) 79 (Botox) 66 Manufacturers and Distributors 2007 Clinical Trial/Research Results Crawford, A.M. Supplier errors in deliveries to (Orange Guide) Pharmaceutical Press 172 Trial shows benefits of blood pressure lowering the pharmacy of a large Dublin teaching hospital Stockley’s Drug Interactions 2007 Pocket treatment for over-80s (Blood Pressure) 494 (Hammond, E./Hospital Pharmacy Issue/ Companion Pharmaceutical Press 246 Clonmel Healthcare Supplier Errors) 302 Successfully Marketing Clinical Trial Results: Clonmel Healthcare’s new corporate identity 105 Creaton, G. Winning in the Healthcare Business Clonmel rebrands its consumer division – A Collaborative Study of Medication Umbach, G. 408 ClonMedica 276 Safety in Four Irish hospitals (Colohan, G./ Textbook of Pharmacoepidemiology Storm, B., Codeine Delaney, T./Harnett, B./Inter-Hospital Study/ Kimmel, S.E. {Eds.} 318-319 Young Scientist Project (2007) – Codeine Kirke, C./Medication Safety/Peer Review/ The Complete Guide to Medical Writing Addiction in Ireland (Addiction) 102 Tighe, P.) 68-73 Stuart, M.C. {Ed.} 318 Colds (see Cough) Pain control in post-operative patients Boots Collins, R. Biopharmaceuticals – the new weapon (Murphy, P.G.M./Pain) 353-356 Reckitt Benckiser acquisition of Boots Healthcare of choice in the battle against disease Crohn’s Disease International (Reckitt Benckiser) 21 (Biopharmaceuticals) 166-169 CHMP give Humira® (adalimumab)
Load more

Recommended publications
  • Cross Reaction Guide
    Individual Reaction Key Methadone(MTD) Phencyclidine(PCP) Amphetamines(AMP) Tricyclic Antidepressants(TCA) Oxycodone(OXY) Barbiturates(BAR) Methamphetamines(MET) Benzodiazepines(BZO) Tramadol(TML) Opiates(OPI, MOP, MOR) Marijuana(THC) Ecstasy(MDMA) Cotinine(COT) Cocaine(COC) Buprenorphine(BUP) Propoxyphene(PPX) Non-reactive Multiple Reaction Key MET and AMP OPI and OXY MDMA and MET MDMA and AMP MET and TCA Generic Name of Compound Trade Name of Compound Results 6-Acetylmorphine N/A Positive: Opiates(OPI, MOP, MOR) Aceta, Acephen, Apacet, Dapacen, Feverall, Acetaminophen (aka Paracetamol) Tylenol, Excedrin (combination), Panadol, Non-reactive Tempra Acetaminophen with Codeine (aka Positive: Opiates(OPI, MOP, MOR) Tylenol 3, Tylenol with Codeine Paracetamol with Codeine) Potential reactants: Dihydrocodeine Acetophenetidin Phenacetin Non-reactive Aspirin, Anadin, Anasin, Bufferin, Caprin, Acetylsalicyclic Acid Disprin, Ecotrin, Empirin, Excedrin Non-reactive (combination) Allobarbital N/A Positive: Barbiturates(BAR) Alphenol N/A Positive: Barbiturates(BAR) Positive: Benzodiazepines(BZO) Potential Alprazolam Xanax reactants: Oxaprozin (Daypro), Sertraline Aluminum Chloride Hexahydrate Drichlor, Anhydrol Forte Non-reactive Alu-Cap, Alisone, Gastrocote, Kolanticon, Aluminum Hydroxide Non-reactive Maalox TC, Mucogel, Pyrogastrone, Topal Alverine Citrate Spasmonal, Spasmonal Fibre Non-reactive Amantadine Symmetrel Positive: Amphetamines(AMP) SpearesMedical.comAminopyrine N/A Non-reactive Elavil, Lentizol, Tryptizol, Triptafen, Triptafen- Amitriptyline
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • With Nicotine Replacement Therapies in Smoking Cessation Vol
    Health Technology Assessment Health Technology Health Technology Assessment 2008; Vol. 12: No. 2 2008; 12: No. 2 Vol. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis D Wang, M Connock, P Barton, A Fry-Smith, P Aveyard and D Moore Feedback The HTA Programme and the authors would like to know your views about this report. The Correspondence Page on the HTA website (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. February 2008 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing.
    [Show full text]
  • PDF (Irish Pharmacist January 2020)
    EXCLUSIVE COVERAGE FROM THE RECENT IRISH MEDICATION SAFETY NETWORK ANNUAL CONFERENCE ABOUT-TURN WE LOOK AT WHAT MIGHT BE NEXT FOR PHARMACISTS FOLLOWING THE REVERSAL IN PROPOSED FEE CUTS DUMB AND DUMBER? ARE PHARMACISTS A LITTLE LACKING IN GREY MATTER WHEN IT COMES TO PRICING, ASKS FINTAN MOORE PLUS CLINICAL CONTENT: ASTHMA ❋ COPD ❋ EYE CARE ❋ SMOKING CESSATION TENDER CARE AT Every Change For topical use only. Cleanse and dry the affected area before applying. A copy of the summary of product characteristics is available upon request. The active ingredient in Caldesene Medicated Powder is Calcium Undecylenate 10% w/w, 20g, 55g, 100g pack size. For supply through general sale. PA 126/152/1 PA Holder: Clonmel Healthcare Ltd., Waterford Road, Clonmel, Co. Tipperary. Date Prepared: October 2019. 2019/ADV/CAL/150H NEW TREATS HEARTBURN AND ACID REFLUX. ONE TABLET PER DAY. LASTS 24 HOURS. AVAILABLE IN PACKS OF 7s AND 14s. Marketed by CCF:22656 Date of preparation: (10-19) ABBREVIATED PRESCRIBING INFORMATION Product Name: Emazole Control 20 mg Gastro-Resistant Tablets Composition: Each tablet contains 20 mg esomeprazole (as magnesium dihydrate). Description: Light pink oval film coated tablet. Indication(s): Proton Pump Inhibitor (PPI): Short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: Swallow tablets whole with liquid, do not chew or crush. Disperse in half a glass of non-carbonated water if difficulty in swallowing. Stir until tablets disintegrate, drink liquid with pellets immediately or within 15 min, or administer through a gastric tube. Do not chew or crush pellets. Adults: The recommended dose is 20 mg esomeprazole (one tablet) per day.
    [Show full text]
  • Paul M Mahan Matthews
    17 April 2015 PAUL McMAHAN MATTHEWS [email protected] PRIMARY APPOINTMENTS July, 2014- Edmond and Lily Safra Professor of Translational Neuroscience and Therapeutics, Division of Brain Sciences, Department of Medicine, Imperial College London Secured endowment for, and first holder of, new Chair associated with the Divisional Head and posts (Edmond and Lily Safra Scholars) accompanying its foundation. April, 2012- Professor and Head, Division of Brain Sciences, Department of Medicine, Imperial College London Leading a new integration of over 70 academics all clinical and basic neurosciences, neuropsychopharmacology, neurology and mental health within a Division of 200 staff in the Faculty of Medicine with senior management responsibilities across the three academic hospital sites of Imperial College, London. Additional responsibilities as Deputy Director (2008- ) of the Wellcome Trust- GSK Translational Medicine Training Programme, Deputy Director (2011- ) of the BRC Institute for Translational Medicine and Therapeutics, Biomedical Research Centre (BRC) Theme Lead for Neuroscience, co-Director of the Neurotechnology Network and the EPSRC Centre for Doctoral Training in Neurology and Research Advisory Board for the Data Science Institute. July, 2012- February 2014 Vice-President for Integrative Medicines Development, Neurosciences and Medicine Development Lead, GlaxoSmithKline (joint appointment with Imperial College) Leading late phase development programme. Senior advisor to the Head of Neurosciences and China R and D with specific
    [Show full text]
  • Formulation of Novel Buccal Mucosal Drug Delivery Systems for Nicotine Replacement Therapy (Nrt)
    FORMULATION OF NOVEL BUCCAL MUCOSAL DRUG DELIVERY SYSTEMS FOR NICOTINE REPLACEMENT THERAPY (NRT). OBINNA CHIKWADO OKEKE A thesis submitted in partial fulfilment of the requirements of the University of Greenwich for the Degree of Doctor of Philosophy January 2017 DECLARATION “I certify that this work has not been accepted in substance for any degree, and is not concurrently being submitted for any purpose. I also declare that this work is the result of my own investigations except where otherwise identified by references and that I have not plagiarised another’s work”. Mr. Obinna C. Okeke (Candidate) Dr J.S. Boateng (First supervisor) i ACKNOWLEDGEMENTS I would like to express my sincere gratitude to my supervisor, Dr Joshua Boateng, for his enormous support, encouragement and general guidance throughout my research. His constant support and encouragement has led me to believe in myself and give out my best. I also appreciate the University of Greenwich for providing the facilities and student support within this period. I would like to acknowledge Dr Ian Slipper for all SEM and XRPD techniques as well as Devyani Amin for HPLC analysis. Thanks to all University staff for supporting my program. I also want to extend my deepest gratitude to my family. Their support and encouragement have led me to the person I am today. I am grateful to Dr Sam and Samantha Owusu-Ware and family for their support. Finally, to all my roommates, officemates, library IT and assistance team, project students under my supervision and fellow postgraduate students, I want to say I big thank you for your support.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • TOX/See Drug Screen Test
    LB0004363 TM TOX/See Drug Screen Test TOX/See TM Cross-Reactivity Table by Trade Name This document is for informational use only; it is not intended to replace confirmative testing. TOX/See TM Drug Screen Test CONCENTRATION COMPOUND (Generic Name) COMPOUND (Trade Name) RESULTS FOR POSITIVE Abacavir Ziagen Non-reactive ,, Acamprosate Campral Non-reactive Acetaminophen (See also Paracetamol) Aceta Non-reactive Acetaminophen (See also Paracetamol) Acephen Non-reactive Acetaminophen (See also Paracetamol) Apacet Non-reactive Acetaminophen (See also Paracetamol) Dapacen Non-reactive Acetaminophen (See also Paracetamol) Feverall Non-reactive ' ' ·,, Acetaminophen (See also Paracetamol) Tylenol Non-reactive ' Acetaminophen (See also Paracetamol) Excedrin (combination) Non-reactive ,, ' :· Acetaminophen (See also Paracetamol) Panadol Non-reactive f.,1· ··<!:•:•· •: '; ,.; .. ·,. Acetaminophen (See also Paracetamol) Tempra Non-reactive ):., '' ·.·~- with Codeine Positive for Opiates MOR= 300 ng/ml Acetaminophen Tylenol3 l<see also Paracetamol with codeine) I(OPI , MOR) OPI = 2,000 ng/ml Positive for Opiates MOR= 300 ng/ml Acetaminophen with Codeine Tylenol with codeine l(see also Paracetamol with codeine) I<OPI, MOR) OPI = 2,000 ng/ml Acetic Acid Ethanoic Acid Non-reactive ~:~w-~{'"·.:;; .. Acetophenetidin Phenacetin Non-reactive f<:;~·§;~j.,;:; ~::: Acetylsalicyclic acid Aspirin Non-reactive 'f.~;k;,';J~:,·; ';~rr. Acetylsalicyclic acid Anadin Non-reactive ' ;': ' f.i~:j~ :;f.: ~. '• Acetylsalicyclic acid Ana sin Non-reactive 1 ;.;:·.\~~·~:;:~,
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • GSK Annual Report 2002
    The Impact of Medicines Do more, feel better, live longer Annual Report 2002 www.gsk.com Mission Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer. Our Spirit We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency. Strategic Intent We want to become the indisputable leader in our industry. GlaxoSmithKline plc is an English public limited company. Its shares are listed on the London Stock Exchange and the New York Stock Exchange. GlaxoSmithKline plc acquired Glaxo Wellcome plc and SmithKline Beecham plc on 27th December 2000 by way of a scheme of arrangement for the merger of the two companies which became effective on 27th December 2000. This report is the Annual Report of GlaxoSmithKline plc for the year ended 31st December 2002. It comprises in a single document the Annual Report of the company in accordance with United Kingdom requirements and the Annual Report on Form 20-F to the Securities and Exchange Commission in the United States of America. A summary report on the year, the Annual Review 2002, intended for the investor not needing the full detail of the Annual Report, is produced as a separate document. The Annual Review includes the joint statement by the Chairman and the Chief Executive Officer, a summary review of operations, summary financial statements and a summary remuneration report.
    [Show full text]
  • Formulary 12 Edition
    Drug and Therapeutics Committee Formulary 12 th Edition Version14.3 July 2015 Compiled on behalf of the Drug and Therapeutics Committee by Eleanore Atkinson Medicines Information Pharmacist Formulary 12 th Edition [v14.3] Contents Introduction ..................................................................................................................................... 11 Purpose ............................................................................................................................................... 11 How to use this Formulary .................................................................................................................. 11 Prescribing Formulary drugs............................................................................................................... 11 Prescribing a non-Formulary drug ...................................................................................................... 11 Procedure for additions to and amendment of the Formulary ............................................................. 11 Prescribing information ....................................................................................................................... 12 Filling in prescription charts ............................................................................................................... 12 Intravenous antibiotics ........................................................................................................................ 12 Controlled drugs ................................................................................................................................
    [Show full text]
  • Copyright Notice
    www.generics-bulletin.com Bulletin Publishing Group 4 Poplar Road, Dorridge, Solihull B93 8DB, UK Tel: +44 (0)1564 777550 Fax: +44 (0)1564 777524 E-mail: [email protected] COPYRIGHT NOTICE This publication must not be forwarded, exported, distributed or circulated by any means or in any format to persons including clients outside the direct employment of your Company. You may distribute the publication internally, but you may incorporate only insubstantial extracts, abstractsbulletin or summaries into presentations, providing Generics is identified as the source of the information. bulletin bulletin The publication/s, Generics and/or News@Generics , in PDF and/or HTML format, are supplied to you strictly under the terms and conditions of the Global Licence agreement between your Company and OTC Publications Ltd, the copyright holder of the publications. The publication/s are the intellectual property of the Publisher, OTC Publications Ltd and are protected by English copyright, trademark and other laws. Bulletin Publishing Group is a division of OTC Publications Ltd Registered Office: 4 Poplar Road, Dorridge, Solihull B93 8DB, UK. Registered in England No 2765878 Gen 21/3/14 Pg. 1_Gen 18/11/05 Pg. 1 17/03/2014 19:47 Page 1 21 March 2014 COMPANY NEWS 2 Council fits missing part Alvotech finesses its biotech production 2 Sun facility suffers an FDAimportalert 3 Lannett pursues buys as sales shoot ahead 4 Hikma commits to its US Generics unit 5 into patent courtpuzzle Aspen wants partner to push into Japan 6 legal compromise reached by the Council of the European Union (EU) is “the last ScinoPharm benefits from 7 focus on Japan Amissing part forthe establishment of Europe-wide patent protection” through aUnified Patent Court, the European Commissionhas claimed.
    [Show full text]